Back to top
more

Thermo Fisher Scientific (TMO)

(Delayed Data from NYSE)

$484.79 USD

484.79
2,006,605

+7.38 (1.55%)

Updated Aug 13, 2025 04:00 PM ET

After-Market: $484.81 +0.02 (0.00%) 4:52 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (153 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Zacks Equity Research

LabCorp (LH) to Expand Oncology Portfolio With Latest Buyout

by Zacks Equity Research

LabCorp's (LH) acquisition of PGDx will position the company at the forefront of driving better patient outcomes in oncology.

Zacks Equity Research

Here's Why You Should Hold on to Integra (IART) Stock for Now

by Zacks Equity Research

Investors are optimistic about Integra's (IART) strong third-quarter performance and ongoing recovery across its business.

Urmimala Biswas headshot

Forget Zimmer Biomet (ZBH), Buy These 3 Medical Devices Stocks

by Urmimala Biswas

With orthopedic stocks like Zimmer Biomet (ZBH) are grappling with several issues, it is wise to invest in medical device stocks like TMO, NEOG and CERN instead for 2022.

Zacks Equity Research

Here's Why You Should Retain Patterson Companies (PDCO) Stock

by Zacks Equity Research

Patterson Companies (PDCO) continues to benefit from strength in Animal Health business and dental business.

Zacks Equity Research

BD (BDX) Partners With Retailers for At-Home COVID-19 Test

by Zacks Equity Research

BD (BDX) collaborates with retail partners and distributors to make the BD Veritor At-Home COVID-19 Test widely accessible.

Zacks Equity Research

Quidel (QDEL) Inks Buyout Deal to Solidify Its Diagnostics Arm

by Zacks Equity Research

Quidel's (QDEL) latest buyout is expected to expand its point-of-care diagnostics portfolio as well as geographic footprint.

Zacks Equity Research

Thermo Fisher (TMO) Releases New Update for Omicron Detection

by Zacks Equity Research

Thermo Fisher's (TMO) TaqMan SARS-CoV-2 Mutation Panel currently offers direct identification of the novel variant of concern.

Zacks Equity Research

Hologic (HOLX) to Meet High Testing Demand With Panther Trax

by Zacks Equity Research

Hologic's (HOLX) Panther Trax scalable solutions will meet the needs of today's laboratories, enabling them to expand operational capacity and testing volumes.

Zacks Equity Research

Thermo Fisher Scientific (TMO) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Thermo Fisher Scientific (TMO) closed the most recent trading day at $650.70, moving -0.15% from the previous trading session.

Zacks Equity Research

Medtronic (MDT) to Gain From Expanded Medicare Coverage for CGM

by Zacks Equity Research

CMS' expanded Medicare coverage includes continuous glucose monitors that can be integrated with Medtronic's (MDT) insulin pumps.

Zacks Equity Research

BD's (BDX) Latest Buyout to Enhance its Digital Capabilities

by Zacks Equity Research

BD's (BDX) acquisition of Scanwell is expected to significantly transform its at-home solutions both at present and in the future.

Zacks Equity Research

Here's Why You Should Retain Merit Medical (MMSI) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Merit Medical (MMSI) owing to its potential in the Peripheral Intervention arm and a strong product portfolio.

Zacks Equity Research

Exact Sciences (EXAS) Rides on Cologuard Sales Amid COVID Fear

by Zacks Equity Research

Exact Sciences (EXAS) is planning several key milestones to bring six innovative cancer diagnostics from its pipeline to patients in need.

Zacks Equity Research

Here's Why You Should Retain Henry Schein (HSIC) Stock for Now

by Zacks Equity Research

Investors are optimistic about Henry Schein's (HSIC) better-than-expected third-quarter results and robust performances by its operating businesses.

Zacks Equity Research

Here's Why You Should Retain Quest Diagnostics (DGX) Stock Now

by Zacks Equity Research

Investors are optimistic about Quest Diagnostics' (DGX) strong third-quarter performance and raised guidance.

Zacks Equity Research

Thermo Fisher Scientific (TMO) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Thermo Fisher Scientific (TMO) closed at $651.70, marking a +0.99% move from the previous day.

Zacks Equity Research

Here's Why You Should Retain Masimo (MASI) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Masimo (MASI) owing to its focus on patient-monitoring.

Zacks Equity Research

Zimmer Biomet (ZBH) Americas Business Slows Down Amid Pandemic

by Zacks Equity Research

Zimmer Biomet (ZBH) continues to face COVID-induced challenges and market pressure.

Zacks Equity Research

Cerner's (CERN) Acquisition by Oracle to Boost Patient Outcome

by Zacks Equity Research

Cerner's (CERN) buyout is likely to aid in growing its community presence as well as improve patient outcomes.

Zacks Equity Research

STERIS (STE) Plans Sale of Non-Core Arm for Debt Repayment

by Zacks Equity Research

The latest spin-off of STERIS' (STE) Renal Care business is expected to partly reduce the company's debt burden.

Trina Mukherjee headshot

3 Promising Gene Sequencing Stocks to Watch Out For in 2022

by Trina Mukherjee

Here we look at three stocks, PKI, TMO and TXG, with robust genome sequencing capabilities that investors can keep a watch on.

Zacks Equity Research

Here's Why You Should Hold on to Medtronic (MDT) Stock for Now

by Zacks Equity Research

Investors are optimistic about Medtronic's (MDT) better-than-expected earnings in the fiscal second quarter and robust performance of the Diabetes arm.

Zacks Equity Research

Here's Why You Should Add LabCorp (LH) to Your Portfolio Now

by Zacks Equity Research

Investors are optimistic about LabCorp's (LH) strong third-quarter 2021 results and raised guidance.

Zacks Equity Research

Integra (IART) Businesses Rebound Despite Supply Issues

by Zacks Equity Research

Integra's (IART) ongoing sales recovery across geographies and product lines looks encouraging.

Zacks Equity Research

Avanos Medical (AVNS) Set to Acquire OrthogenRx for $160M

by Zacks Equity Research

Avanos Medical's (AVNS) deal to acquire OrthogenRx is likely to boost the company's chronic pain portfolio.